Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06089954 · ClinicalTrials.gov registry record · NA
Penn Medicine Biobank Return of Results Program
A NA study, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- NA
- Development phase
- 2,500
- Enrollment target
NCT06089954: Active NA study, sponsored by Abramson Cancer Center at Penn Medicine.
NCT06089954 is a NA study that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 2,500 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06089954, a NA study, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 2,500 participants
- Enrollment target
Study Summary
The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to answer are: * Is sharing actionable genetic research results with participants through a multimedia patient-informed eHealth intervention (e.g. patient portal) no worse than sharing results by telephone or videoconference with a genetic counselor? * Will research participants access an eHealth educational intervention or chatbot education to learn about research results being offered and the option to decline learning their individual research results and how frequently participants choose to decline actionable research results? * Who benefits less and more from digital intervention with return of actionable research results and what barriers exist to using these tools for return of research results outside this study? Participants in the biobank will be offered digital tools to learn about research results being offered and the option to decline receiving these results. Those who don't decline and have an actionable result will be randomly assigned to receive their results with a genetic counselor or through an eHealth portal. Participants will complete surveys before and after receipt of results to understand patient experiences with these methods of education and return of results to determine if digital tools can be used to help ensure more patients get access to research results which could impact their health.
Primary Outcome
Will be evaluated using an adapted version of the Know Gene Scale, a 16-item assessment administered to patients after genetic testing and/or genetic counseling to measure their understanding of the health implications of genetic testing results. The scale uses three responses, Agree, Disagree, and Don't Know, as response to a statement about genetics. Final scores range from 0-16, with a higher score indicating a better outcome for knowledge.
Interventions
- OTHER private web-portal eHealth disclosure of genetic results
- OTHER eHealth education intervention (web or chatbot)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2023-10-20 |
| Est. Completion | 2026-09-30 |
| Phase | NA |
What the registry record for NCT06089954 still lists
NCT06089954 is an interventional study that assigns participants to a tested intervention. Its 2,500 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% higher).
The record links to 0 conditions, and to 2 interventions - of which private web-portal eHealth disclosure of genetic results is the first listed.
NCT06089954 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06089954 about?
NCT06089954 is a clinical study titled "Penn Medicine Biobank Return of Results Program". The goal of this hybrid type 1 effectiveness-implementation study is to evaluate and compare different ways of delivering genetic research results to participants. The main questions the study aims to answer are: * Is sharing actionable genetic research results with participants through a multimedi...
What is the current status of trial NCT06089954?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 2,500 participants. The study started on 2023-10-20. Estimated completion is 2026-09-30.
What interventions are being tested in trial NCT06089954?
The interventions under investigation include: private web-portal eHealth disclosure of genetic results (OTHER), eHealth education intervention (web or chatbot) (OTHER).
Who is sponsoring clinical trial NCT06089954?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06089954's enrollment target sits among peer trials
2,500 44th of 2000 higher than 1,956 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001160 · 2,500 participants
Studies on Tumors of the Thyroid
- NCT01904188 · 2,500 participants
Clinical Microbial Species & Antibiotic Resistance ID in ED Patients Presenting With Infection - is Rapid ID Possible & Accurate?
- NCT02257229 · 2,500 participants
Prospective Evaluation of Treatment for Clubfoot
- NCT02530658 · 2,500 participants
Next Generation Sequencing of Normal Tissues Prospectively in Pediatric Oncology Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI